GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: August 22, 2003, 15:06:54 ; Search time 86 Seconds
(without alignments)
645.980 Million cell updates/sec

Title: US-09-745-506-37
Perfect score: 350
Sequence: 1 MDLKALLSSLNDFASLSFAE.....LENKINIILSETDRDPLQVV 350

Scoring table: OLIGO
Gapop 60.0 , Gapext 60.0

Searched: 1107863 seqs, 158726573 residues

Word size : 0

Total number of hits satisfying chosen parameters: 1107863

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Database : A_Geneseq_19Jun03:*
1: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*
24: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2003.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	350	100.0	350	22	AAG81361	Human AFP protein
2	350	100.0	350	22	AAB94573	Human protein sequ
3	350	100.0	383	22	AAM88085	Human immune/haema
4	296	84.6	377	22	AAU27744	Human full-length
5	268	76.6	351	22	AAB60663	Human gene express
6	211	60.3	247	23	ABB08182	Human protein kina
7	102	29.1	110	22	ABG20985	Novel human diagno
8	68	19.4	68	22	ABG52473	Human liver peptid
9	68	19.4	68	22	ABB32385	Peptide #5036 enco
10	68	19.4	68	22	ABB37667	Peptide #5173 enco
11	68	19.4	68	22	AAM58295	Human brain expres
12	68	19.4	68	22	AAM18609	Peptide #5043 enco
13	68	19.4	68	22	AAM06178	Peptide #4860 enco
14	49	14.0	79	22	AAU21467	Human novel foetal
15	43	12.3	146	22	AAU27916	Human contig polyp
16	38	10.9	70	22	ABG20982	Novel human diagno
17	25	7.1	74	22	ABG20984	Novel human diagno
18	10	2.9	360	22	AAG82528	S. epidermidis ope
19	10	2.9	367	23	ABP38833	Staphylococcus epi
20	8	2.3	64	22	AAU21906	Human cardiovascul
21	7	2.0	15	18	AAW19390	Human calpastatin
22	7	2.0	39	22	ABG51377	Human liver peptid
23	7	2.0	39	22	ABB31324	Peptide #3975 enco
24	7	2.0	39	22	ABB36530	Peptide #4036 enco
25	7	2.0	39	22	ABB21871	Protein #3870 enco
26	7	2.0	39	22	AAM57293	Human brain expres
27	7	2.0	39	22	AAM69697	Human bone marrow
28	7	2.0	39	22	AAM17509	Peptide #3943 enco
29	7	2.0	39	22	AAM30031	Peptide #4068 enco
30	7	2.0	39	22	AAM05181	Peptide #3863 enco
31	7	2.0	39	23	ABG39312	Human peptide enco
32	7	2.0	52	21	AAG56482	Arabidopsis thalia
33	7	2.0	52	21	AAG58744	Arabidopsis thalia
34	7	2.0	56	23	ABP42537	Human ovarian anti
35	7	2.0	66	22	AAU54473	Propionibacterium
36	7	2.0	68	15	AAR46082	DEAD ATP helicase
37	7	2.0	80	22	AAM96296	Human reproductive
38	7	2.0	93	22	AAG78718	Human pterin-molyb
39	7	2.0	116	21	AAB09953	Rice disease resis
40	7	2.0	119	22	AAE11178	Mycobacterium aviu
41	7	2.0	141	22	ABB71967	Drosophila melanog
42	7	2.0	157	21	AAG17053	Arabidopsis thalia
43	7	2.0	164	22	ABB70532	Drosophila melanog
44	7	2.0	166	23	ABP51404	Human MDDT SEQ ID
45	7	2.0	168	22	AAB93880	Human protein sequ

ALIGNMENTS

RESULT 1
AAG81361
ID AAG81361 standard; Protein; 350 AA.
XX
AC AAG81361;
XX
DT 10-SEP-2001 (first entry)
XX
DE Human AFP protein sequence SEQ ID NO:240.
XX
KW Human; secreted protein; secretion; bacterial cell; fungal cell;
KW eukaryotic cell; fusion protein; maltose binding protein;
KW immunoglobulin constant region; polyhistidine tag.
XX
OS Homo sapiens.
XX
PN WO200129221-A2.
XX
PD 26-APR-2001.
XX
PF 20-OCT-2000; 2000WO-US29052.
XX
PR 20-OCT-1999; 99US-0160712.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Conklin DC, Yee DP;
XX
DR WPI; 2001-300340/31.
DR N-PSDB; AAH52212.
XX
PT Isolated polypeptide for directing secretion of proteins of interest

PT from a host cell including, e.g. bacteria, includes contiguous amino
PT acid residues of polypeptide with specified amino acids -
XX
PS Claim 1; Page 424-425; 617pp; English.
XX
CC AAH52093 to AAH52303 encode the human secreted proteins given in AAG81242
CC to AAG81453. The secreted proteins can be used for directing the
CC secretion of proteins of interest from a host cell including bacteria,
CC fungal cells, and cultured higher eukaryotic cells. The present invention
CC also describes fusion proteins, where a secreted protein of the invention
CC is operably linked via a peptide bond or peptide linker to a second
CC protein selected from the group consisting of maltose binding protein,
CC an immunoglobulin constant region, a polyhistidine tag and a peptide
CC given in AAG81453.
XX
SQ Sequence 350 AA;

Query Match 100.0%; Score 350; DB 22; Length 350;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 350; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MDLKALLSSLNDFASLSFAESWDNVGLLVEPSPPHTVNTLFLTNDLTEEVMEEVLQKKAD 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MDLKALLSSLNDFASLSFAESWDNVGLLVEPSPPHTVNTLFLTNDLTEEVMEEVLQKKAD 60

Qy         61 LILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGVNNWLAKGLGA 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 LILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGVNNWLAKGLGA 120

Qy        121 CTSRPIHPSKAPNYPTEGNHRVEFNVNYTQDLDKVMSAVKGIDGVSVTSFSARTGNEEQT 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CTSRPIHPSKAPNYPTEGNHRVEFNVNYTQDLDKVMSAVKGIDGVSVTSFSARTGNEEQT 180

Qy        181 RINLNCTQKALMQVVDFLSRNKQLYQKTEILSLEKPLLLHTGMGRLCTLDESVSLATMID 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 RINLNCTQKALMQVVDFLSRNKQLYQKTEILSLEKPLLLHTGMGRLCTLDESVSLATMID 240

Qy        241 RIKRHLKLSHIRLALGVGRTLESQVKVVALCAGSGSSVLQGVEADLYLTGEMSHHDTLDA 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 RIKRHLKLSHIRLALGVGRTLESQVKVVALCAGSGSSVLQGVEADLYLTGEMSHHDTLDA 300

Qy        301 ASQGINVILCEHSNTERGFLSDLRDMLDSHLENKINIILSETDRDPLQVV 350
              |||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 ASQGINVILCEHSNTERGFLSDLRDMLDSHLENKINIILSETDRDPLQVV 350
```

RESULT 2
AAB94573
ID AAB94573 standard; Protein; 350 AA.
XX
AC AAB94573;
XX
DT 26-JUN-2001 (first entry)
XX
DE Human protein sequence SEQ ID NO:15360.
XX
KW Human; primer; detection; diagnosis; antisense therapy; gene therapy.
XX
OS Homo sapiens.
XX
PN EP1074617-A2.
XX
PD 07-FEB-2001.
XX
PF 28-JUL-2000; 2000EP-0116126.
XX
PR 29-JUL-1999; 99JP-0248036.
PR 27-AUG-1999; 99JP-0300253.
PR 11-JAN-2000; 2000JP-0118776.
PR 02-MAY-2000; 2000JP-0183767.
PR 09-JUN-2000; 2000JP-0241899.
XX
PA (HELI-) HELIX RES INST.
XX
PI Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;
PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;
XX
DR WPI; 2001-318749/34.
XX
PT Primer sets for synthesizing polynucleotides, particularly the 5602
PT full-length cDNAs defined in the specification, and for the detection
PT and/or diagnosis of the abnormality of the proteins encoded by the
PT full-length cDNAs -
XX
PS Claim 8; SEQ ID 15360; 2537pp + CD ROM; English.
XX
CC The present invention describes primer sets for synthesising 5602
CC full-length cDNAs defined in the specification. Where a primer set
CC comprises: (a) an oligo-dT primer and an oligonucleotide complementary
CC to the complementary strand of a polynucleotide which comprises one of
CC the 5602 nucleotide sequences defined in the specification, where the
CC oligonucleotide comprises at least 15 nucleotides; or (b) a combination
CC of an oligonucleotide comprising a sequence complementary to the
CC complementary strand of a polynucleotide which comprises a 5'-end
CC sequence and an oligonucleotide comprising a sequence complementary to a
CC polynucleotide which comprises a 3'-end sequence, where the
CC oligonucleotide comprises at least 15 nucleotides and the combination of
CC the 5'-end sequence/3'-end sequence is selected from those defined in
CC the specification. The primer sets can be used in antisense therapy and
CC in gene therapy. The primers are useful for synthesising polynucleotides,
CC particularly full-length cDNAs. The primers are also useful for the
CC detection and/or diagnosis of the abnormality of the proteins encoded by
CC the full-length cDNAs. The primers allow obtaining of the full-length
CC cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to
CC AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632
CC represent oligonucleotides, all of which are used in the exemplification
CC of the present invention.
XX
SQ Sequence 350 AA;

Query Match 100.0%; Score 350; DB 22; Length 350;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 350; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MDLKALLSSLNDFASLSFAESWDNVGLLVEPSPPHTVNTLFLTNDLTEEVMEEVLQKKAD 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MDLKALLSSLNDFASLSFAESWDNVGLLVEPSPPHTVNTLFLTNDLTEEVMEEVLQKKAD 60

Qy         61 LILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGVNNWLAKGLGA 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 LILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGVNNWLAKGLGA 120

Qy        121 CTSRPIHPSKAPNYPTEGNHRVEFNVNYTQDLDKVMSAVKGIDGVSVTSFSARTGNEEQT 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CTSRPIHPSKAPNYPTEGNHRVEFNVNYTQDLDKVMSAVKGIDGVSVTSFSARTGNEEQT 180

Qy        181 RINLNCTQKALMQVVDFLSRNKQLYQKTEILSLEKPLLLHTGMGRLCTLDESVSLATMID 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 RINLNCTQKALMQVVDFLSRNKQLYQKTEILSLEKPLLLHTGMGRLCTLDESVSLATMID 240

Qy        241 RIKRHLKLSHIRLALGVGRTLESQVKVVALCAGSGSSVLQGVEADLYLTGEMSHHDTLDA 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 RIKRHLKLSHIRLALGVGRTLESQVKVVALCAGSGSSVLQGVEADLYLTGEMSHHDTLDA 300

Qy        301 ASQGINVILCEHSNTERGFLSDLRDMLDSHLENKINIILSETDRDPLQVV 350
              |||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 ASQGINVILCEHSNTERGFLSDLRDMLDSHLENKINIILSETDRDPLQVV 350
```

RESULT 3
AAM88085
ID AAM88085 standard; Protein; 383 AA.
XX
AC AAM88085;
XX

DT 07-NOV-2001 (first entry)
XX
DE Human immune/haematopoietic antigen SEQ ID NO:15678.
XX
KW Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW cytostatic; gene therapy; vaccine; metastasis.
XX
OS Homo sapiens.
XX
PN WO200157182-A2.
XX
PD 09-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01354.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.

```
PR   08-DEC-2000; 2000US-0251869.
PR   08-DEC-2000; 2000US-0251989.
PR   08-DEC-2000; 2000US-0251990.
PR   11-DEC-2000; 2000US-0254097.
PR   05-JAN-2001; 2001US-0259678.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Barash SC,  Ruben SM;
XX
DR   WPI; 2001-483426/52.
DR   N-PSDB; AAK60866.
XX
PT   Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT   useful for preventing, diagnosing and/or treating cancers and
PT   metastasis -
XX
PS   Claim 11; SEQ ID NO 15678; 3071pp + Sequence Listing; English.
XX
CC   AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)
CC   amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
CC   activity, and can be used in gene therapy and vaccine production. (I)
CC   proteins and polynucleotides may be used in the prevention, diagnosis and
CC   treatment of diseases associated with inappropriate (I) expression. For
CC   example, they may be used to treat disorders associated with decreased
CC   expression by rectifying mutations or deletions in a patient's genome
CC   that affect the activity of (I) by expressing inactive proteins or to
CC   supplement the patients own production of (I). Additionally, (I)
CC   polynucleotides may be used to produce the secreted (I), by inserting
CC   the nucleic acids into a host cell and culturing the cell to express the
CC   protein. (I) proteins and polynucleotides may be used to prevent,
CC   diagnose and treat immune/haematopoietic-related diseases, especially
CC   cancers and cancer metastases of haematopoietic-derived cells. AAK64703
CC   to AAK87694 represent human immune/haematopoietic antigen genomic
CC   sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC   represent sequences used in the exemplification of the present invention.
XX
SQ   Sequence   383 AA;

  Query Match             100.0%;  Score 350;  DB 22;  Length 383;
  Best Local Similarity   100.0%;  Pred. No. 0;
  Matches  350;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MDLKALLSSLNDFASLSFAESWDNVGLLVEPSPPHTVNTLFLTNDLTEEVMEEVLQKKAD 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         34 MDLKALLSSLNDFASLSFAESWDNVGLLVEPSPPHTVNTLFLTNDLTEEVMEEVLQKKAD 93

Qy         61 LILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGVNNWLAKGLGA 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         94 LILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGVNNWLAKGLGA 153

Qy        121 CTSRPIHPSKAPNYPTEGNHRVEFNVNYTQDLDKVMSAVKGIDGVSVTSFSARTGNEEQT 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        154 CTSRPIHPSKAPNYPTEGNHRVEFNVNYTQDLDKVMSAVKGIDGVSVTSFSARTGNEEQT 213

Qy        181 RINLNCTQKALMQVVDFLSRNKQLYQKTEILSLEKPLLLHTGMGRLCTLDESVSLATMID 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        214 RINLNCTQKALMQVVDFLSRNKQLYQKTEILSLEKPLLLHTGMGRLCTLDESVSLATMID 273

Qy        241 RIKRHLKLSHIRLALGVGRTLESQVKVVALCAGSGSSVLQGVEADLYLTGEMSHHDTLDA 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        274 RIKRHLKLSHIRLALGVGRTLESQVKVVALCAGSGSSVLQGVEADLYLTGEMSHHDTLDA 333

Qy        301 ASQGINVILCEHSNTERGFLSDLRDMLDSHLENKINIILSETDRDPLQVV 350
              |||||||||||||||||||||||||||||||||||||||||||||||||
Db        334 ASQGINVILCEHSNTERGFLSDLRDMLDSHLENKINIILSETDRDPLQVV 383


RESULT 4
AAU27744
ID   AAU27744 standard; Protein; 377 AA.
XX
AC   AAU27744;
XX
DT   18-DEC-2001  (first entry)
XX
DE   Human full-length polypeptide sequence #69.
XX
KW   Mammal; human; rhesus monkey; baker's yeast; fission yeast; Norway rat;
KW   mouse; Chinese hamster; African clawed frog; fruit fly; dog; leukaemia;
KW   cancer; lymphoma; neuroblastoma; autoimmune disorder; cell proliferation;
KW   nervous system disorder; inflammatory disorder; cell differentiation;
KW   angiogenesis; stem cell growth factor; activin; inhibin; cartilage; burn;
KW   genetic disorder; bone regeneration; tendon; ligament; tissue repair;
KW   cytostatic; antirheumatic; antiarthritic; vulnerary; antiinflammatory;
KW   antibacterial; immunosuppressive; vasotropic; antiparkinsonian;
KW   neuroprotective; osteopathic; antidiabetic; antiasthmatic; antiallergic;
KW   immunostimulant; analgesic; gene therapy.
XX
OS   Homo sapiens.
XX
PN   WO200164834-A2.
XX
PD   07-SEP-2001.
XX
PF   26-FEB-2001; 2001WO-US04926.
XX
PR   28-FEB-2000; 2000US-0515126.
PR   18-MAY-2000; 2000US-0577409.
PR   17-JUN-2000; 2000US-0597707.
PR   14-JUL-2000; 2000US-0616807.
PR   19-SEP-2000; 2000US-0664641.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT,  Liu C,  Zhou P,  Asundi V,  Zhang J,  Zhao QA,  Ren F;
PI   Xue AJ,  Yang Y,  Wehrman T,  Wang J,  Ma Y,  Wang D,  Chen R,  Xu C;
PI   Drmanac R;
XX
DR   WPI; 2001-589862/66.
DR   N-PSDB; AAS44644.
XX
PT   Novel polypeptides and nucleic acids obtained from cDNA libraries
PT   prepared from various human tissues, for diagnosis, treatment of
PT   cancer, neurological, inflammatory disorders and for use in arrays for
PT   detection -
XX
PS   Claim 10; SEQ ID No 241; 153pp; English.
XX
CC   Sequences AAU27676-AAU28019 represent full-length polypeptides and
CC   contig polypeptides of the invention. The proteins and their associated
CC   DNA sequences are useful for the treatment, diagnosis and prevention of
CC   various types of disorder in a mammalian subject such as a human, dog,
CC   monkey, mouse, hamster or rat. The disorders include cancers such as
CC   leukaemia, lymphoma and neuroblastoma, autoimmune disorders such as
CC   multiple sclerosis, connective tissue disease, rheumatoid arthritis,
CC   diabetes mellitus, allergic rhinitis, asthma and eczema, nervous system
CC   disorders such as Parkinson's disease, Alzheimer's disease, Huntington's
CC   chorea, amyotrophic lateral sclerosis, spinal muscular atrophy and
CC   Wernicke disease, inflammatory disorders such as nephritis, Crohn's
CC   disease, ischaemia-reperfusion injury, shock, sepsis and inflammatory
CC   bowel disease. The sequences exhibit activity relating to angiogenesis,
CC   cell proliferation, cell differentiation, stem cell growth factor,
CC   activin or inhibin. Therefore, they can be used to manipulate stem cells
CC   in culture to give rise to neuroepithelial cells that can be used to
CC   augment or replace cells damaged by illness, accidental damage or genetic
CC   disorders. The sequences may also be used for regeneration of bone,
CC   cartilage, tendons and ligaments and in tissue repair and burn healing.
CC   Note: Some sequences for this patent did not form part of the printed
CC   specification, but were obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   377 AA;

  Query Match             84.6%;  Score 296;  DB 22;  Length 377;
  Best Local Similarity   100.0%;  Pred. No. 8.4e-279;
```

```
  Matches  296;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MDLKALLSSLNDFASLSFAESWDNVGLLVEPSPPHTVNTLFLTNDLTEEVMEEVLQKKAD 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         28 MDLKALLSSLNDFASLSFAESWDNVGLLVEPSPPHTVNTLFLTNDLTEEVMEEVLQKKAD 87

Qy         61 LILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGVNNWLAKGLGA 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         88 LILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGVNNWLAKGLGA 147

Qy        121 CTSRPIHPSKAPNYPTEGNHRVEFNVNYTQDLDKVMSAVKGIDGVSVTSFSARTGNEEQT 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        148 CTSRPIHPSKAPNYPTEGNHRVEFNVNYTQDLDKVMSAVKGIDGVSVTSFSARTGNEEQT 207

Qy        181 RINLNCTQKALMQVVDFLSRNKQLYQKTEILSLEKPLLLHTGMGRLCTLDESVSLATMID 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        208 RINLNCTQKALMQVVDFLSRNKQLYQKTEILSLEKPLLLHTGMGRLCTLDESVSLATMID 267

Qy        241 RIKRHLKLSHIRLALGVGRTLESQVKVVALCAGSGSSVLQGVEADLYLTGEMSHHD 296
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        268 RIKRHLKLSHIRLALGVGRTLESQVKVVALCAGSGSSVLQGVEADLYLTGEMSHHD 323
```

RESULT 5
AAB60663
ID AAB60663 standard; Protein; 351 AA.
XX
AC AAB60663;
XX
DT 04-MAY-2001 (first entry)
XX
DE Human gene expression regulatory factor-related protein hNIF3-s.
XX
KW Human gene expression regulatory factor-related protein; hNIF3-s;
KW NGG1-interacting factor; haemopoietic stem cell; preparation;
KW detection.
XX
OS Homo sapiens.
XX
PN CN1272543-A.
XX
PD 08-NOV-2000.
XX
PF 11-APR-2000; 2000CN-0115369.
XX
PR 11-APR-2000; 2000CN-0115369.
XX
PA (NANF-) NANFANG RES CENT STATE HUMAN GENE GROUP.
XX
PI Li N, Xiao H, Liu F;
XX
DR WPI; 2001-183596/19.
DR N-PSDB; AAF59945.
XX
PT Human gene expression regulatory factor related protein and its coded
PT sequence -
XX
PS Claim 4; Page 19-20; 20pp; Chinese.
XX
CC The invention relates to a novel human gene expression regulatory
CC factor-related protein, hNIF3-s (NGG1-interacting factor, AAB60663),
CC and cDNA encoding it (AAF59945). hNIF3-s is expressed in haemopoietic
CC stem cells. The invention also relates to the preparation of hNIF3-s
CC proteins and nucleic acids, and the detection of hNIF3-s proteins and
CC nucleic acids in a sample. The present sequence represents hNIF3-s.
XX
SQ Sequence 351 AA;

```
  Query Match             76.6%;  Score 268;  DB 22;  Length 351;
  Best Local Similarity   100.0%;  Pred. No. 1.3e-251;
  Matches  268;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         83 ERLVIRALENRVGIYSPHTAYDAAPQGVNNWLAKGLGACTSRPIHPSKAPNYPTEGNHRV 142
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         84 ERLVIRALENRVGIYSPHTAYDAAPQGVNNWLAKGLGACTSRPIHPSKAPNYPTEGNHRV 143

Qy        143 EFNVNYTQDLDKVMSAVKGIDGVSVTSFSARTGNEEQTRINLNCTQKALMQVVDFLSRNK 202
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        144 EFNVNYTQDLDKVMSAVKGIDGVSVTSFSARTGNEEQTRINLNCTQKALMQVVDFLSRNK 203

Qy        203 QLYQKTEILSLEKPLLLHTGMGRLCTLDESVSLATMIDRIKRHLKLSHIRLALGVGRTLE 262
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        204 QLYQKTEILSLEKPLLLHTGMGRLCTLDESVSLATMIDRIKRHLKLSHIRLALGVGRTLE 263

Qy        263 SQVKVVALCAGSGSSVLQGVEADLYLTGEMSHHDTLDAASQGINVILCEHSNTERGFLSD 322
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        264 SQVKVVALCAGSGSSVLQGVEADLYLTGEMSHHDTLDAASQGINVILCEHSNTERGFLSD 323

Qy        323 LRDMLDSHLENKINIILSETDRDPLQVV 350
              ||||||||||||||||||||||||||||
Db        324 LRDMLDSHLENKINIILSETDRDPLQVV 351
```

RESULT 6
ABB08182
ID ABB08182 standard; Protein; 247 AA.
XX
AC ABB08182;
XX
DT 23-SEP-2002 (first entry)
XX
DE Human protein kinase C 27.17 polypeptide.
XX
KW Human; protein kinase C 27.17; protein metabolism; enzyme.
XX
OS Homo sapiens.
XX
PN CN1333355-A.
XX
PD 30-JAN-2002.
XX
PF 07-JUL-2000; 2000CN-0117049.
XX
PR 07-JUL-2000; 2000CN-0117049.
XX
PA (SHAN-) SHANGHAI BIODOOR GENE DEV CO LTD.
XX
PI Mao Y, Xie Y;
XX
DR WPI; 2002-305609/35.
DR N-PSDB; ABL60919.
XX
PT Human protein kinase C 27.17 polypeptide and its encoding
PT polynucleotide, for treating e.g. protein metabolism disturbance -
XX
PS Claim 1; Page 26-27 (disclosure); 33pp; Chinese.
XX
CC The invention relates to a human protein kinase C 27.17 polypeptide and
CC its encoding polynucleotide. The polypeptide can be expressed by standard
CC DNA recombination. The polynucleotide, polypeptide and its antagonist are
CC useful for treating e.g. protein metabolism disturbance. The present
CC sequence represents the human protein kinase C 27.17 polypeptide.
XX
SQ Sequence 247 AA;

```
  Query Match             60.3%;  Score 211;  DB 23;  Length 247;
  Best Local Similarity   100.0%;  Pred. No. 2.2e-196;
  Matches  211;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        140 HRVEFNVNYTQDLDKVMSAVKGIDGVSVTSFSARTGNEEQTRINLNCTQKALMQVVDFLS 199
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         37 HRVEFNVNYTQDLDKVMSAVKGIDGVSVTSFSARTGNEEQTRINLNCTQKALMQVVDFLS 96

Qy        200 RNKQLYQKTEILSLEKPLLLHTGMGRLCTLDESVSLATMIDRIKRHLKLSHIRLALGVGR 259
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         97 RNKQLYQKTEILSLEKPLLLHTGMGRLCTLDESVSLATMIDRIKRHLKLSHIRLALGVGR 156
```

```
Qy        260 TLESQVKVVALCAGSGSSVLQGVEADLYLTGEMSHHDTLDAASQGINVILCEHSNTERGF 319
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        157 TLESQVKVVALCAGSGSSVLQGVEADLYLTGEMSHHDTLDAASQGINVILCEHSNTERGF 216

Qy        320 LSDLRDMLDSHLENKINIILSETDRDPLQVV 350
              |||||||||||||||||||||||||||||||
Db        217 LSDLRDMLDSHLENKINIILSETDRDPLQVV 247
```

RESULT 7
ABG20985
ID ABG20985 standard; Protein; 110 AA.
XX
AC ABG20985;
XX
DT 18-FEB-2002 (first entry)
XX
DE Novel human diagnostic protein #20976.
XX
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS Homo sapiens.
XX
PN WO200175067-A2.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001WO-US08631.
XX
PR 31-MAR-2000; 2000US-0540217.
PR 23-AUG-2000; 2000US-0649167.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Drmanac RT, Liu C, Tang YT;
XX
DR WPI; 2001-639362/73.
DR N-PSDB; AAS85172.
XX
PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of mutations
PT responsible for genetic disorders or other traits and to assess
PT biodiversity -
XX
PS Claim 20; SEQ ID No 51344; 103pp; English.
XX
CC The invention relates to isolated polynucleotide (I) and
CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC and gene mapping, and in recombinant production of (II). The
CC polynucleotides are also used in diagnostics as expressed sequence tags
CC for identifying expressed genes. (I) is useful in gene therapy techniques
CC to restore normal activity of (II) or to treat disease states involving
CC (II). (II) is useful for generating antibodies against it, detecting or
CC quantitating a polypeptide in tissue, as molecular weight markers and as
CC a food supplement. (II) and its binding partners are useful in medical
CC imaging of sites expressing (II). (I) and (II) are useful for treating
CC disorders involving aberrant protein expression or biological activity.
CC The polypeptide and polynucleotide sequences have applications in
CC diagnostics, forensics, gene mapping, identification of mutations
CC responsible for genetic disorders or other traits to assess biodiversity
CC and to produce other types of data and products dependent on DNA and
CC amino acid sequences. ABG00010-ABG30377 represent novel human
CC diagnostic amino acid sequences of the invention.
CC Note: The sequence data for this patent did not appear in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 110 AA;

Query Match 29.1%; Score 102; DB 22; Length 110;
Best Local Similarity 100.0%; Pred. No. 8.2e-91;
Matches 102; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        174 TGNEEQTRINLNCTQKALMQVVDFLSRNKQLYQKTEILSLEKPLLLHTGMGRLCTLDESV 233
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          2 TGNEEQTRINLNCTQKALMQVVDFLSRNKQLYQKTEILSLEKPLLLHTGMGRLCTLDESV 61

Qy        234 SLATMIDRIKRHLKLSHIRLALGVGRTLESQVKVVALCAGSG 275
              |||||||||||||||||||||||||||||||||||||||||||
Db         62 SLATMIDRIKRHLKLSHIRLALGVGRTLESQVKVVALCAGSG 103
```

RESULT 8
ABG52473
ID ABG52473 standard; Peptide; 68 AA.
XX
AC ABG52473;
XX
DT 25-FEB-2003 (first entry)
XX
DE Human liver peptide, SEQ ID No 31121.
XX
KW Human; liver; cirrhosis; hyperlipoproteinaemia; hyperlipidaemia;
KW hypercholesterolaemia; coronary heart disease.
XX
OS Homo sapiens.
XX
PN WO200157273-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00664.
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488898/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for
PT analysing gene expression in human adult liver -
XX
PS Claim 27; SEQ ID No 31121; 658pp; English.
XX
CC The invention relates to a single exon nucleic acid probe (SENP) (I) for
CC measuring human gene expression in a sample derived from human adult
CC liver, comprising one of 13109 defined nucleotide sequences given in the
CC specification (or complements/ fragments). The probe hybridises at high
CC stringency to a nucleic acid molecule expressed in the human adult
CC liver. (I) may be used for predicting, measuring and displaying gene
CC expression in samples derived from human adult liver. The genes
CC identified may be involved in genetic liver diseases such as cirrhosis,
CC hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which
CC is associated with coronary heart disease. ABG47348-ABG59930 represent
CC human liver single exon encoded peptides of the invention.
CC Note: The sequence information for this patent does not appear in the
CC printed specification but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 68 AA;

Query Match 19.4%; Score 68; DB 22; Length 68;
Best Local Similarity 100.0%; Pred. No. 5.7e-58;
Matches 68; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          51 MEEVLQKKADLILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGV 110
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db           1 MEEVLQKKADLILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGV 60

Qy         111 NNWLAKGL 118
               ||||||||
Db          61 NNWLAKGL 68


RESULT 9
ABB32385
ID   ABB32385 standard; Peptide; 68 AA.
XX
AC   ABB32385;
XX
DT   01-FEB-2002  (first entry)
XX
DE   Peptide #5036 encoded by breast cell single exon nucleic acid probe.
XX
KW   Human; microarray; single exon probe; gene expression; breast;
KW   disease; cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157271-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00662.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-496933/54.
XX
PT   New spatially-addressable set of single exon nucleic acid probes,
PT   useful for measuring gene expression in sample derived from human
PT   breast, comprises number of single exon nucleic acid probes  -
XX
PS   Claim 27; SEQ ID NO 15353; 327pp + sequence listing; English.
XX
CC   The invention relates to a spatially-addressable set of single exon
CC   nucleic acid probes for measuring gene expression in a sample derived
CC   from human breast and BT 474 cells. The method involves contacting
CC   the probes with a collection of detectably labelled nucleic acids
CC   derived from mRNA of human breast, and then measuring the label
CC   bound to each probe of the microarray. The probes are useful for
CC   verifying the expression of regions of genomic DNA predicted to
CC   encode proteins. They are useful for gene discovery, and for
CC   determining predisposition and/or prognosing breast disease. Gene
CC   expression analysis is useful for assessing the toxicity of chemical
CC   agents on cells. The microarray of this invention presents a far greater
CC   diversity of probes for measuring gene expression, with far less bias
CC   than expressed sequence tag microarrays. The method is suitable for
CC   rapid production of functional information from genomic sequence. The
CC   present sequence is a peptide encoded by a single exon nucleic acid
CC   probe of the invention.
CC   Note: The sequence data for this patent did not form part of the
CC   printed specification, but was obtained in electronic format directly
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   68 AA;

  Query Match             19.4%;  Score 68;  DB 22;  Length 68;
  Best Local Similarity   100.0%;  Pred. No. 5.7e-58;
  Matches   68;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          51 MEEVLQKKADLILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGV 110
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db           1 MEEVLQKKADLILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGV 60

Qy         111 NNWLAKGL 118
               ||||||||
Db          61 NNWLAKGL 68


RESULT 10
ABB37667
ID   ABB37667 standard; Peptide; 68 AA.
XX
AC   ABB37667;
XX
DT   04-FEB-2002  (first entry)
XX
DE   Peptide #5173 encoded by human foetal liver single exon probe.
XX
KW   Human; foetal liver; gene expression; single exon nucleic acid probe.
XX
OS   Homo sapiens.
XX
PN   WO200157277-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00669.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483447/52.
XX
PT   Human genome-derived single exon nucleic acid probes useful for
PT   analyzing gene expression in human fetal liver -
XX
PS   Claim 27; SEQ ID NO 30302; 639pp + sequence listing; English.
XX
CC   The invention relates to a single exon nucleic acid probe for
CC   measuring human gene expression in a sample derived from human foetal
CC   liver. The single exon nucleic acid probes may be used for predicting,
CC   measuring and displaying gene expression in samples derived from human
CC   fetal liver. The present sequence is a peptide encoded by a single exon
CC   nucleic acid probe of the invention.
CC   Note: The sequence data for this patent did not form part of the
CC   printed specification, but was obtained in electronic format directly
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   68 AA;

  Query Match             19.4%;  Score 68;  DB 22;  Length 68;
  Best Local Similarity   100.0%;  Pred. No. 5.7e-58;
  Matches   68;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          51 MEEVLQKKADLILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGV 110
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db           1 MEEVLQKKADLILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGV 60

Qy         111 NNWLAKGL 118
               ||||||||
```

```
Db         61 NNWLAKGL 68


RESULT 11
AAM58295
ID   AAM58295 standard; Protein; 68 AA.
XX
AC   AAM58295;
XX
DT   05-NOV-2001  (first entry)
XX
DE   Human brain expressed single exon probe encoded protein SEQ ID NO: 30400.
XX
KW   Human; brain expressed exon; gene expression analysis; probe;
KW   microarray; Alzheimer's disease; multiple sclerosis; schizophrenia;
KW   epilepsy; cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157275-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00667.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483446/52.
XX
PT   Single exon nucleic acid probes for analyzing gene expression in human
PT   brains -
XX
PS   Example 4; SEQ ID NO: 30400; 650pp + Sequence Listing; English.
XX
CC   The present invention provides a number of single exon nucleic acid
CC   probes which are derived from genomic sequences expressed in the human
CC   brain. They can be used to measure gene expression in brain cell samples,
CC   which may enable the diagnosis and improved treatment of nervous system
CC   diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC   epilepsy and cancers. The present sequence is a protein encoded by one of
CC   the probes of the invention.
XX
SQ   Sequence   68 AA;

  Query Match             19.4%;  Score 68;  DB 22;  Length 68;
  Best Local Similarity   100.0%;  Pred. No. 5.7e-58;
  Matches   68;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         51 MEEVLQKKADLILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGV 110
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MEEVLQKKADLILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGV 60

Qy        111 NNWLAKGL 118
              ||||||||
Db         61 NNWLAKGL 68


RESULT 12
AAM18609
ID   AAM18609 standard; Protein; 68 AA.
XX
AC   AAM18609;
XX
DT   12-OCT-2001  (first entry)
XX
DE   Peptide #5043 encoded by probe for measuring cervical gene expression.
XX
KW   Probe; human; microarray; gene expression; cervical epithelial cell;
KW   cervical cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157278-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00670.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488901/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for
PT   analyzing gene expression in human cervical epithelial cells -
XX
PS   Claim 27; SEQ ID No 23435; 487pp; English.
XX
CC   The present invention relates to human single exon nucleic acid probes
CC   (SENP: see AAI10068-AAI28459). The present sequence is a peptide encoded
CC   by one such probe. The SENPs are derived from human HeLa cells. The SENPs
CC   can be used to produce a single exon microarray, which can be used for
CC   measuring human gene expression in a sample derived from human cervical
CC   epithelial cells. By measuring gene expression, the probes are therefore
CC   useful in grading and/or staging of diseases of the cervix, notably
CC   cervical cancer.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   68 AA;

  Query Match             19.4%;  Score 68;  DB 22;  Length 68;
  Best Local Similarity   100.0%;  Pred. No. 5.7e-58;
  Matches   68;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         51 MEEVLQKKADLILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGV 110
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MEEVLQKKADLILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGV 60

Qy        111 NNWLAKGL 118
              ||||||||
Db         61 NNWLAKGL 68


RESULT 13
AAM06178
ID   AAM06178 standard; Protein; 68 AA.
XX
AC   AAM06178;
XX
DT   09-OCT-2001  (first entry)
XX
DE   Peptide #4860 encoded by probe for measuring breast gene expression.
XX
KW   Probe; human; breast disease; breast cancer; development disorder;
KW   inflammatory disease; proliferative breast disease; non-carcinoma tumour.
```

```
XX
OS   Homo sapiens.
XX
PN   WO200157270-A2.
XX
PD   09-AUG-2001.
XX
PF   29-JAN-2001; 2001WO-US00661.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-476286/51.
XX
PT   Novel single exon nucleic acid probe used to measuring gene expression
PT   in a human breast -
XX
PS   Claim 27; SEQ ID No 14918; 322pp; English.
XX
CC   The present invention relates to novel single exon nucleic acid probes
CC   (see AAI00010-AAI10067). The present sequence is a peptide encoded by one
CC   such probe. The probes are useful for measuring human gene expression in
CC   a human breast sample, where the probe hybridises at high stringency to a
CC   nucleic acid expressed in the human breast. The probes are useful for
CC   predicting, diagnosing, grading, staging, monitoring and prognosing
CC   diseases of the human breast, particularly those diseases with polygenic
CC   aetiology. The diseases include: breast cancer, disorders of development,
CC   inflammatory diseases of the breast, fibrocystic changes, proliferative
CC   breast disease and non-carcinoma tumours.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   68 AA;

  Query Match            19.4%;  Score 68;  DB 22;  Length 68;
  Best Local Similarity  100.0%;  Pred. No. 5.7e-58;
  Matches   68;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         51 MEEVLQKKADLILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGV 110
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MEEVLQKKADLILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGV 60

Qy        111 NNWLAKGL 118
              ||||||||
Db         61 NNWLAKGL 68


RESULT 14
AAU21467
ID   AAU21467 standard; Protein; 79 AA.
XX
AC   AAU21467;
XX
DT   18-DEC-2001  (first entry)
XX
DE   Human novel foetal antigen, SEQ ID NO 1711.
XX
KW   Human; foetal tissue antigen; antiinflammatory; neuroprotective;
KW   immunomodulator; cardiovascular; cytostatic; nephrothropic;
KW   cardiovascular; autoimmune disease; rheumatoid arthritis;
KW   hyperproliferative disorder; breast neoplasm; cancer;
KW   cardiovascular disorder; cardiac arrest; cerebrovascular disorder;
KW   cerebral ischaemia; angiogenesis; nervous system disorder;
KW   Alzheimer's disease; infection; ocular disorder; corneal infection;
KW   wound healing; epithelial cell proliferation; food additive.
XX
OS   Homo sapiens.
XX
PN   WO200155312-A2.
XX
PD   02-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US01321.
XX
PR   31-JAN-2000; 2000US-0179065.
PR   04-FEB-2000; 2000US-0180628.
PR   24-FEB-2000; 2000US-0184664.
PR   02-MAR-2000; 2000US-0186350.
PR   16-MAR-2000; 2000US-0189874.
PR   17-MAR-2000; 2000US-0190076.
PR   18-APR-2000; 2000US-0198123.
PR   19-MAY-2000; 2000US-0205515.
PR   07-JUN-2000; 2000US-0209467.
PR   28-JUN-2000; 2000US-0214886.
PR   30-JUN-2000; 2000US-0215135.
PR   07-JUL-2000; 2000US-0216647.
PR   07-JUL-2000; 2000US-0216880.
PR   11-JUL-2000; 2000US-0217487.
PR   11-JUL-2000; 2000US-0217496.
PR   14-JUL-2000; 2000US-0218290.
PR   26-JUL-2000; 2000US-0220963.
PR   26-JUL-2000; 2000US-0220964.
PR   14-AUG-2000; 2000US-0224518.
PR   14-AUG-2000; 2000US-0224519.
PR   14-AUG-2000; 2000US-0225213.
PR   14-AUG-2000; 2000US-0225214.
PR   14-AUG-2000; 2000US-0225266.
PR   14-AUG-2000; 2000US-0225267.
PR   14-AUG-2000; 2000US-0225268.
PR   14-AUG-2000; 2000US-0225270.
PR   14-AUG-2000; 2000US-0225447.
PR   14-AUG-2000; 2000US-0225757.
PR   14-AUG-2000; 2000US-0225758.
PR   14-AUG-2000; 2000US-0225759.
PR   18-AUG-2000; 2000US-0226279.
PR   22-AUG-2000; 2000US-0226681.
PR   22-AUG-2000; 2000US-0226868.
PR   22-AUG-2000; 2000US-0227182.
PR   23-AUG-2000; 2000US-0227009.
PR   30-AUG-2000; 2000US-0228924.
PR   01-SEP-2000; 2000US-0229287.
PR   01-SEP-2000; 2000US-0229343.
PR   01-SEP-2000; 2000US-0229344.
PR   01-SEP-2000; 2000US-0229345.
PR   05-SEP-2000; 2000US-0229509.
PR   05-SEP-2000; 2000US-0229513.
PR   06-SEP-2000; 2000US-0230437.
PR   06-SEP-2000; 2000US-0230438.
PR   08-SEP-2000; 2000US-0231242.
PR   08-SEP-2000; 2000US-0231243.
PR   08-SEP-2000; 2000US-0231244.
PR   08-SEP-2000; 2000US-0231413.
PR   08-SEP-2000; 2000US-0231414.
PR   08-SEP-2000; 2000US-0232080.
PR   08-SEP-2000; 2000US-0232081.
PR   12-SEP-2000; 2000US-0231968.
PR   14-SEP-2000; 2000US-0232397.
PR   14-SEP-2000; 2000US-0232398.
PR   14-SEP-2000; 2000US-0232399.
PR   14-SEP-2000; 2000US-0232400.
PR   14-SEP-2000; 2000US-0232401.
PR   14-SEP-2000; 2000US-0233063.
PR   14-SEP-2000; 2000US-0233064.
PR   14-SEP-2000; 2000US-0233065.
PR   21-SEP-2000; 2000US-0234223.
PR   21-SEP-2000; 2000US-0234274.
```

PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-488782/53.
DR N-PSDB; AAS34287.
XX
PT New polynucleotides and polypeptides for diagnosing, treating,
PT preventing or prognosing e.g. diseases or disorders of the nervous,
PT musculoskeletal, excretory, gastrointestinal, reproductive, and
PT respiratory systems -
XX
PS Claim 11; SEQ ID No 1711; 642pp; English.
XX
CC The invention relates to novel nucleic acids encoding novel human foetal
CC antigens. The nucleic acids and proteins are used to prevent, treat (e.g.
CC by gene therapy) or ameliorate a medical condition in e.g. humans, mice,
CC rabbits, goats, horses, cats, dogs, chickens or sheep. They
CC are also used in diagnosing a pathological condition or susceptibility
CC to a pathological condition. The antibodies to the antigens can also
CC be used in alleviating symptoms associated with the disorders and in
CC diagnostic immunoassays e.g. radioimmunoassays or enzyme linked
CC immunosorbent assays (ELISA). Disorders which are diagnosed or treated
CC include autoimmune diseases e.g. rheumatoid arthritis,
CC hyperproliferative disorders e.g. neoplasms of the breast or liver,
CC cardiovascular disorders e.g. cardiac arrest, cerebrovascular disorders
CC e.g. cerebral ischaemia, angiogenesis, nervous system disorders e.g.
CC Alzheimer's disease, infections caused by bacteria, viruses and fungi
CC and ocular disorders e.g. corneal infection. The polypeptides can also
CC be used to aid wound healing and epithelial cell proliferation, to
CC prevent skin aging due to sunburn, to maintain organs before
CC transplantation, for supporting cell culture of primary tissues, to
CC regenerate tissues and in chemotaxis. The polypeptides can also be used
CC as a food additive or preservative to increase or decrease storage
CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC minerals, cofactors and other nutritional components. Numerous
CC examples of diseases and disorders treated by the nucleic acids and
CC proteins are given in the specification. The present sequence

Query Match 14.0%; Score 49; DB 22; Length 79;
Best Local Similarity 100.0%; Pred. No. 1.9e-39;
Matches 49; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 118 LGACTSRPIHPSKAPNYPTEGNHRVEFNVNYTQDLDKVMSAVKGIDGVS 166
||||||||||||||||||||||||||||||||||||||||||||||||||
Db 15 LGACTSRPIHPSKAPNYPTEGNHRVEFNVNYTQDLDKVMSAVKGIDGVS 63

RESULT 15
AAU27916
ID AAU27916 standard; Protein; 146 AA.
XX
AC AAU27916;
XX
DT 18-DEC-2001 (first entry)
XX
DE Human contig polypeptide sequence #69.
XX
KW Mammal; human; rhesus monkey; baker's yeast; fission yeast; Norway rat;
KW mouse; Chinese hamster; African clawed frog; fruit fly; dog; leukaemia;
KW cancer; lymphoma; neuroblastoma; autoimmune disorder; cell proliferation;
KW nervous system disorder; inflammatory disorder; cell differentiation;
KW angiogenesis; stem cell growth factor; activin; inhibin; cartilage; burn;
KW genetic disorder; bone regeneration; tendon; ligament; tissue repair;
KW cytostatic; antirheumatic; antiarthritic; vulnerary; antiinflammatory;
KW antibacterial; immunosuppressive; vasotropic; antiparkinsonian;
KW neuroprotective; osteopathic; antidiabetic; antiasthmatic; antiallergic;
KW immunostimulant; analgesic; gene therapy.
XX
OS Homo sapiens.
OS Synthetic.

XX
PN WO200164834-A2.
XX
PD 07-SEP-2001.
XX
PF 26-FEB-2001; 2001WO-US04926.
XX
PR 28-FEB-2000; 2000US-0515126.
PR 18-MAY-2000; 2000US-0577409.
PR 17-JUN-2000; 2000US-0597707.
PR 14-JUL-2000; 2000US-0616807.
PR 19-SEP-2000; 2000US-0664641.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Zhou P, Asundi V, Zhang J, Zhao QA, Ren F;
PI Xue AJ, Yang Y, Wehrman T, Wang J, Ma Y, Wang D, Chen R, Xu C;
PI Drmanac R;
XX
DR WPI; 2001-589862/66.
DR N-PSDB; AAS44816.
XX
PT Novel polypeptides and nucleic acids obtained from cDNA libraries
PT prepared from various human tissues, for diagnosis, treatment of
PT cancer, neurological, inflammatory disorders and for use in arrays for
PT detection -
XX
PS Claim 10; Page 132; 153pp; English.
XX
CC Sequences AAU27676-AAU28019 represent full-length polypeptides and
CC contig polypeptides of the invention. The proteins and their associated
CC DNA sequences are useful for the treatment, diagnosis and prevention of
CC various types of disorder in a mammalian subject such as a human, dog,
CC monkey, mouse, hamster or rat. The disorders include cancers such as
CC leukaemia, lymphoma and neuroblastoma, autoimmune disorders such as
CC multiple sclerosis, connective tissue disease, rheumatoid arthritis,
CC diabetes mellitus, allergic rhinitis, asthma and eczema, nervous system
CC disorders such as Parkinson's disease, Alzheimer's disease, Huntington's
CC chorea, amyotrophic lateral sclerosis, spinal muscular atrophy and
CC Wernicke disease, inflammatory disorders such as nephritis, Crohn's
CC disease, ischaemia-reperfusion injury, shock, sepsis and inflammatory
CC bowel disease. The sequences exhibit activity relating to angiogenesis,
CC cell proliferation, cell differentiation, stem cell growth factor,
CC activin or inhibin. Therefore, they can be used to manipulate stem cells
CC in culture to give rise to neuroepithelial cells that can be used to
CC augment or replace cells damaged by illness, accidental damage or genetic
CC disorders. The sequences may also be used for regeneration of bone,
CC cartilage, tendons and ligaments and in tissue repair and burn healing.
CC Note: Some sequences for this patent did not form part of the printed
CC specification, but were obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 146 AA;

Query Match 12.3%; Score 43; DB 22; Length 146;
Best Local Similarity 100.0%; Pred. No. 2.2e-33;
Matches 43; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 ALLSSLNDFASLSFAESWDNVGLLVEPSPPHTVNTLFLTNDLT 47
||||||||||||||||||||||||||||||||||||||||||||
Db 36 ALLSSLNDFASLSFAESWDNVGLLVEPSPPHTVNTLFLTNDLT 78

Search completed: August 22, 2003, 15:17:00
Job time : 87 secs